Delayed at the EMA, a gene therapy player is grappling with a cash crunch

John Carroll

Editor & Founder

Five months after GenSight was forced by a manufacturing snafu to delay its EMA application for their gene therapy to treat Leber hereditary optic neuropathy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Delayed at the EMA, a gene therapy player is grappling with a cash crunch

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

At least seven drugmakers say they will participate in round two of IRA negotiations

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics

How AI can address ongoing challenges in the life sciences industry

De­layed at the EMA, a gene ther­a­py play­er is grap­pling with a cash crunch

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Delayed at the EMA, a gene therapy player is grappling with a cash crunch